Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Veterinary Oncology Market, by Animal Type
1.4.2 North America Veterinary Oncology Market, by Therapy
1.4.3 North America Veterinary Oncology Market, by Cancer Type
1.4.4 North America Veterinary Oncology Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements : 2016, Sep – 2019, Nov) Leading Players
Chapter 4. North America Veterinary Oncology Market by Animal Type
4.1 North America Canine Market by Country
4.2 North America Feline Market by Country
Chapter 5. North America Veterinary Oncology Market by Therapy
5.1 North America Chemotherapy Market by Country
5.2 North America Radiology Market by Country
5.3 North America Surgery Market by Country
5.4 North America Immunotherapy Market by Country
5.5 North America Other Therapy Market by Country
Chapter 6. North America Veterinary Oncology Market by Cancer Type
6.1 North America Lymphoma Market by Country
6.2 North America Mast Cell Cancer Market by Country
6.3 North America Mammary & Squamous Cell Cancer Market by Country
6.4 North America Others Market by Country
Chapter 7. North America Veterinary Oncology Market by Country
7.1 US Veterinary Oncology Market
7.1.1 US Veterinary Oncology Market by Animal Type
7.1.2 US Veterinary Oncology Market by Therapy
7.1.3 US Veterinary Oncology Market by Cancer Type
7.2 Canada Veterinary Oncology Market
7.2.1 Canada Veterinary Oncology Market by Animal Type
7.2.2 Canada Veterinary Oncology Market by Therapy
7.2.3 Canada Veterinary Oncology Market by Cancer Type
7.3 Mexico Veterinary Oncology Market
7.3.1 Mexico Veterinary Oncology Market by Animal Type
7.3.2 Mexico Veterinary Oncology Market by Therapy
7.3.3 Mexico Veterinary Oncology Market by Cancer Type
7.4 Rest of North America Veterinary Oncology Market
7.4.1 Rest of North America Veterinary Oncology Market by Animal Type
7.4.2 Rest of North America Veterinary Oncology Market by Therapy
7.4.3 Rest of North America Veterinary Oncology Market by Cancer Type
Chapter 8. Company Profiles
8.1 Boehringer Ingelheim International GmbH
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Partnerships, Collaborations, and Agreements:
8.1.5.2 Acquisition and Mergers:
8.2 Karyopharm Therapeutics, Inc.
8.2.1 Company overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Regeneus Ltd.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Research & Development Expense
8.4 Elanco Animal Health, Inc.
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.5 Zoetis, Inc.
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 Recent strategies and developments:
8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Varian Medical Systems, Inc.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expense
8.6.5 Recent strategies and developments:
8.6.5.1 Acquisition and Mergers:
8.6.5.2 Partnerships, Collaborations, and Agreements:
8.6.5.3 Product Launches and Product Expansions:
8.7 PetCure Oncology, LLC (Accelitech, LLC)
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Partnerships, Collaborations, and Agreements:
8.8 AB Science SA
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Research & Development Expense
8.9 Rhizen Pharmaceuticals S.A.
8.9.1 Company Overview
8.1 Nippon Zenyaku Kogyo Co., Ltd.
8.10.1 Company Overview
Unique Offerings 